Phuturdex › Diseases › Diabetes
Drugs in development · updated 30 October 2026
Diabetes: drugs in development
As of 30 October 2026 there are 90 active clinical trials (recruiting or ongoing, phases I–III) on 91 drugs for diabetes. 43 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 43 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MetforminRiomet Er®, Glumetza® | II–III | 8 | NCT07033585 |
| DapagliflozinForxiga, Dapagliflozin Propanediol | II–III | 7 | NCT07033585 |
| SemaglutideWegovy, Rybelsus | II–III | 3 | NCT06387199 |
| MetreleptinMyalept®, Myalepta® | III | 2 | NCT02262832 |
| SitagliptinBrynovin®, Zituvio® | III | 2 | NCT07073768 |
| DenosumabProlia, Degevma® | III | 1 | NCT04547348 |
| Edetate DisodiumCalcium Disodium Versenate® | III | 1 | NCT03982693 |
| EsmololEsmolol Hydrochloride Double Strength In Plastic Container®, Esmolol Hydrochloride In Plastic Container® | III | 1 | NCT05769868 |
| FenofibrateFenoglide®, Antara (Micronized)® | III | 1 | NCT01320345 |
| Insulin Degludec InjectionTresiba® | III | 1 | NCT06767748 |
| Insulin icodecAwiqli Flextouch®, Awiqli® | III | 1 | NCT07165223 |
| Onglyza | II–III | 1 | NCT07033585 |
| UstekinumabPyzchiva®, Starjemza® | II–III | 1 | NCT03941132 |
| TirzepatideZepbound, Mounjaro | II | 4 | NCT06820281 |
| PioglitazoneActos, Pioglitazone Accord® | II | 3 | NCT06729996 |
Sorted by most advanced phase and number of active trials. Showing 15 of 48 drugs.
All 91 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Type 2 diabetes 171 drugs
- Type-1 diabetes 80 drugs
- Obesity 233 drugs
- Overweight 139 drugs
- Diabetic Nephropathies 18 drugs
- Diabetic retinopathy 17 drugs
- Gestational diabetes 9 drugs
- Prediabetes 18 drugs
- Insulin resistance 41 drugs
- Cardiovascular disease 71 drugs
- Hypoglycemia 20 drugs
- Chronic renal insufficiency 104 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Endocrine system disease 19 drugs
- Metabolic disease 30 drugs
- Glucose metabolism disease 12 drugs
- Cardiovascular disease 71 drugs
- Vascular disease 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003920 “Diabetes Mellitus”.